CCN2 and polyostotic fibrous dysplasia: We assessed histological architecture, hormone levels, and the immunohistochemical expression of fibrosis-related markers—including TGF-β1, CTGF, PPAR-γ, MMP-2, and MMP-9—to determine whether PFD can ameliorate fibrotic changes and improve ovarian integrity and hormonal balance.